Anti-melanoma antibody mg-21 for diagnosis and therapy of human tumors
CA 1309040 C · Owner: Oncogen Limited Partnership · Inventors: Hellstrom, Ingegerd; Hellstrom, Karl E.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
An antibody MG-21 which is directed against a tumorassociated glycolipid antigen and which is capable of activating serum complement or antibody dependent cellular cytotoxicity is described. This antibody finds use in the therapy of cancers particularly melanoma and glioma. Proper administration of the antibody results in lysis of the tumor cells in vivo.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Granted October 20, 1992. A Canadian patent filed before October 1, 1989 lasted 17 years from grant, so its term ended October 20, 2009.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.